NINTEDANIB — GLENMARK PHARMS LTD, approved 2026-07-09 (ANDA212555).
46,765 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.